GlassScriptPhysician profile
Julia L Betts
NPI 1457682478
$26,619.71
in general payments reported to CMS, 2019-2025
70 companies · $5,680 in 2025
The $5,680 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4,483 · 2022: $5,060 · 2023: $5,280 · 2024: $6,117 · 2025: $5,680.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $17K · Education: $2.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $17,074.73 |
| Education | $2.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,118.78 | 2021-2025 | |
| Ucb, INC. | $2,244.23 | 2021-2025 | Briviact, Rystiggo, Nayzilam |
| Csl Behring | $1,602.44 | 2021-2025 | Hizentra |
| Pfizer INC. | $1,565.77 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $1,435.05 | 2021-2025 | |
| Biogen, INC. | $1,400.40 | 2021-2025 | Vumerity, Tysabri, Avonex |
| Neurocrine Biosciences, INC. | $829.61 | 2021-2025 | Ingrezza, Ongentys |
| Acadia Pharmaceuticals INC | $778.57 | 2021-2025 | Nuplazid |
| Otsuka America Pharmaceutical, INC. | $753.76 | 2023-2025 | Rexulti, Nuedexta |
| Mdd US Operations, LLC | $747.27 | 2023-2025 | Gocovri, Gocovri, Qelbree |
| Emd Serono, INC. | $714.11 | 2021-2025 | Mavenclad |
| Lilly USA, LLC | $693.37 | 2021-2025 | Emgality, Amyvid, Kisunla |
| Argenx US, INC. | $643.07 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Alexion Pharmaceuticals, INC. | $642.57 | 2021-2025 | Ultomiris, Soliris |
| Sk Life Science, INC. | $581.68 | 2021-2025 |
Show all 70 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $580.12 | 2021-2025 | Zeposia |
| Acorda Therapeutics, INC | $544.14 | 2021-2024 | Inbrija, Ampyra |
| Teva Pharmaceuticals USA, INC. | $467.12 | 2021-2025 | Austedo Xr, Austedo Xr |
| Amgen INC. | $458.57 | 2021-2025 | Uplizna, Aimovig |
| Catalyst Pharmaceuticals, INC. | $451.01 | 2021-2025 | Firdapse |
| Kyowa Kirin, INC. | $418.63 | 2021-2024 | Nourianz |
| Merz Pharmaceuticals, LLC | $355.44 | 2021-2025 | Xeomin, Inbrija, Ampyra |
| Ipsen Biopharmaceuticals, INC | $354.02 | 2021-2025 | Dysport |
| Grifols USA, LLC | $319.76 | 2021-2025 | Gamunex-C |
| Biohaven Pharmaceuticals, INC. | $308.36 | 2021 | |
| Sunovion Pharmaceuticals INC. | $306.42 | 2021-2022 | |
| Avanir Pharmaceuticals, INC. | $302.05 | 2021-2022 | |
| Neurelis, INC. | $296.40 | 2021-2023 | Valtoco |
| Jazz Pharmaceuticals INC. | $285.44 | 2021-2025 | |
| Lundbeck LLC | $275.38 | 2021-2025 | Rexulti, Vyepti |
| Harmony Biosciences LLC | $250.00 | 2021-2025 | Wakix |
| Tg Therapeutics, INC. | $221.86 | 2023-2025 | |
| Impel Pharmaceuticals INC. | $203.31 | 2022-2023 | Trudhesa |
| Biohaven Pharmaceutical Holding Company LTD. | $198.91 | 2022 | |
| Sumitomo Pharma America, INC. | $175.34 | 2023-2024 | Aptiom |
| Eisai INC. | $170.20 | 2021-2023 | |
| Genentech USA, INC. | $165.85 | 2022-2024 | Ocrevus, Ocrevus Zunovo |
| Genzyme Corporation | $162.86 | 2021-2025 | |
| Amneal Pharmaceuticals LLC | $151.42 | 2021-2025 | Rytary, Crexont |
| Takeda Pharmaceuticals U.S.A., INC. | $137.13 | 2023-2024 | Hyqvia, Gammagard |
| Impel Pharmaceuticals LLC | $130.86 | 2025 | Trudhesa |
| Cycle Pharmaceuticals INC | $103.17 | 2025 | Bafiertam, Tascenso Odt |
| Merck Sharp & Dohme LLC | $99.38 | 2021-2023 | Belsomra |
| Horizon Therapeutics Plc | $94.54 | 2021-2023 | Uplizna |
| Supernus Pharmaceuticals, INC. | $82.66 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $79.69 | 2021 | |
| Avion Pharmaceuticals | $72.53 | 2022 | |
| Axsome Therapeutics, INC. | $66.04 | 2025 | Symbravo |
| Banner Life Sciences, LLC | $61.18 | 2022-2024 | |
| Arbor Pharmaceuticals, INC. | $44.31 | 2021-2022 | |
| Almatica Pharma LLC | $41.40 | 2021 | |
| Ani Pharmaceuticals, INC. | $37.60 | 2025 | Purified Cortrophin Gel |
| Scilex Pharmaceuticals INC. | $33.85 | 2021-2023 | Ztlido |
| Aucta Pharmaceuticals, INC. | $33.73 | 2024 | Motpoly Xr |
| Idorsia Pharmaceuticals US INC | $31.09 | 2022-2023 | Quviviq |
| Allergan, INC. | $28.85 | 2021 | |
| Currax Pharmaceuticals LLC | $27.99 | 2021-2023 | Onzetra Xsail |
| Janssen Biotech, INC. | $26.28 | 2025 | |
| Corium, LLC | $24.90 | 2023 | Adlarity |
| Immedica Pharma US, INC. | $23.45 | 2023 | |
| Abbott Laboratories | $23.38 | 2021 | |
| Akcea Therapeutics, INC. | $19.10 | 2021 | |
| Upsher-Smith Laboratories LLC | $18.62 | 2021 | |
| Medtronic, INC. | $18.33 | 2022 | |
| Ge Healthcare | $18.04 | 2021 | |
| Vanda Pharmaceuticals INC. | $14.66 | 2024 | Ponvory |
| Tanabe Pharma America, INC. | $14.07 | 2022 | |
| Boston Scientific Corporation | $13.98 | 2021 | |
| Mallinckrodt Hospital Products INC. | $13.73 | 2022 | |
| Sobi, INC | $11.88 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Betts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.